Afatinib 복약 후 발생한 비소세포성 폐암환자의 피부독성 부작용에 대한 한방치료 1례
Traditional Korean Medicine for Skin Toxic Side Effects from Afatinib in a Non-Small Cell Lung Cancer Patient: A Case Report
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objectives: We report a case of traditional Korean medicine (TKM) treatment for skin side effects after taking afatinib (Giotrif®). Methods: A 62-year-old female who was diagnosed with non-small cell lung cancer stage 4 (T4N2M1b) and was on treatment with afatinib (29.56 mg/day for 4 months) complained of skin toxicity as a side effect. For 16 admission days, the patient was treated with acupuncture, moxibustion, and herbal medicine (oral decoction and external ointment). Results: Improvement of skin toxicity was measured by a numeric rating scale. In addition, Quality of life (QOL) was measured using EORTC Quality of Life Questionnaire, Core 30 (EORTC QLQ-C30) and EORTC Quality of Life Questionnaire, 13-item lung cancer–specific module (EORTC QLQ-LC13) Developed by the European Organization for Research and Treatment of Cancer (EORTC). Tumor size and carcinoembryonic antigen (CEA) were also examined during follow up. Conclusions: After a combined TKM treatment, skin toxicity symptoms and quality of life scales were significantly improved with no side effects. The tumor size was not changed on computed tomography during follow-up period. CEA levels were decreased.
Abstract
Objectives: We report a case of traditional Korean medicine (TKM) treatment for skin side effects after taking afatinib (Giotrif®). Methods: A 62-year-old female who was diagnosed with non-small cell lung cancer stage 4 (T4N2M1b) and was on treatment with afatinib (29.56 mg/day for 4 months) complained of skin toxicity as a side effect. For 16 admission days, the patient was treated with acupuncture, moxibustion, and herbal medicine (oral decoction and external ointment). Results: Improvement of skin toxicity was measured by a numeric rating scale. In addition, Quality of life (QOL) was measured using EORTC Quality of Life Questionnaire, Core 30 (EORTC QLQ-C30) and EORTC Quality of Life Questionnaire, 13-item lung cancer–specific module (EORTC QLQ-LC13) Developed by the European Organization for Research and Treatment of Cancer (EORTC). Tumor size and carcinoembryonic antigen (CEA) were also examined during follow up. Conclusions: After a combined TKM treatment, skin toxicity symptoms and quality of life scales were significantly improved with no side effects. The tumor size was not changed on computed tomography during follow-up period. CEA levels were decreased.
참고문헌 (20)
- World Cancer Report, "Stewart B", ~ (2014)
- Horn L, "Harrison's Principles of Internal Medicine", pp.19e~ (2015), McGraw-Hill Education
- D'Angelo SP, "Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib", J Thorac Oncol, 7(12), pp.1815~1822 (2012)
- 이대호, "Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned", Cancer Research and Treatment, 47(4), pp.549~554 (2015), 대한암학회[DOI]
- Sequist LV, "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations", J Clin Oncol, 31(27), pp.3327~3334 (2013)
- Yang JC, "Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin", pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations, 2013, pp.31(27), 3342~3350
- Park JW, "One Case Study of a Non Small Cell Lung Cancer Patient Experienc ing Gefitinib Adverse Effects Managed by Traditional Korean Medicine", J of Kor Traditional Oncology, 17(1), pp.9~16 (2012)
- 윤숙정, "폐암 환자들에서 Gefitinib(Iressa)에 의한 피부 부작용", Tuberculosis and Respiratory Diseases, 61(2), pp.150~156 (2006), 대한결핵및호흡기학회
- Yun YH, "Validation of the Korean version of the EORTC QLQ-C30", Quality of Life Research, 13(4), pp.863~868 (2004)
- 이현재, "표피성장인자 수용체 억제제와 관련된 피부이상반응", 대한피부과학회지, 49(02), pp.131~140 (2011), 대한피부과학회
- Kim YH, "Lung cancer guideline", Korean Association for Lung Cancer, ~ (2010)
- Tsimboukis S, "Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management", Clinical lung cancer, 10(2), pp.106~111 (2009)
- 김경순, "항암플러스 투여로 호전된 진행성 비소세포성 폐암 연속환자증례", 대한한방내과학회지, 30(4), pp.893~900 (2009), 대한한방내과학회
- 손지영, "호흡곤란을 주소로 한 폐암환자의 한방치료 증례보고", 대한한방내과학회지, 30(1), pp.233~240 (2009), 대한한방내과학회
- He W, "Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with first-generation EGFＲ-TKI in treating advanced non-small cell lung cancer", China Journal of Chinese Materia, 42(13), pp.2591~2598 (2017)
- Zhang X, "TCM differentiation and treatment of non-small cell lung cancer targeted drug-related dermal toxicity", J Tradit Chin Med, 56(12), pp.1065~1066 (2015)
- Jeon BH, "Influence of the extract of RADIX ASTRAGALI on the cytotoxicity induced by the chemotherapeutic agents, mitomycion C", J Physiol & Pathol Korean Med, 12(1), pp.55~59 (1998)
- 이진영, "황기의 자외선에 의한 세포 손상을 막는 보호 효과", 생약학회지, 39(4), pp.300~304 (2008), 한국생약학회
- 서승희, "Glycyrrhizae Radix Suppresses Human TNF-α-induced Inflammation Via Blockade of p38 Activation in HaCaT Cells", 한국미용학회지, 19(2), pp.207~214 (2013), 한국미용학회
- Kasymjanova G, "The potential role for acupuncture in treating symptoms in patients with lung cancer: an observational longitudinal study", Curr Oncol, 20(3), pp.152~157 (2013)